SCHEMBL3147335

SCHEMBL3147335

[CH2]CCn1ccccc1=O

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.49
POLB P06746 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
PSMB1 P20618 2/20 0.46
NPC1 O15118 1/20 0.45
MITF O75030 1/20 0.45
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TSHR P16473 1/20 0.41
PLD1 Q13393 1/20 0.38
DRD2 P14416 1/20 0.37
PSMB5 P28074 2/20 0.36
PREP P48147 1/20 0.35
FAP Q12884 1/20 0.35
PDCD1LG2 Q9BQ51 1/20 0.32
CD274 Q9NZQ7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9752595 0.86 L3MBTL1 (0.55) L3MBTL1POLBNPSR1PSMB1NPC1
SCHEMBL9394796 0.82 L3MBTL1 (0.51) L3MBTL1POLBNPSR1PSMB1NPC1
SCHEMBL6108133 0.82
SCHEMBL9752675 0.82 L3MBTL1 (0.51) L3MBTL1POLBNPSR1PSMB1NPC1
SCHEMBL9752719 0.80 L3MBTL1 (0.50) L3MBTL1POLBNPSR1PSMB1NPC1
SCHEMBL9752571 0.80 L3MBTL1 (0.50) L3MBTL1POLBNPSR1PSMB1NPC1
SCHEMBL9752728 0.80 L3MBTL1 (0.50) L3MBTL1POLBNPSR1PSMB1NPC1
SCHEMBL9342969 0.78 PSMB1 (0.50) L3MBTL1POLBNPSR1PSMB1NPC1
SCHEMBL174910 0.78 NPC1 (0.49) L3MBTL1POLBNPSR1PSMB1NPC1
SCHEMBL17842541 0.78 L3MBTL1 (0.49) L3MBTL1POLBNPSR1PSMB1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2197879-B1 C7-SUBSTITUTED CAMPTOTHECIN ANALOGS BIONUMERIK PHARMACEUTICALS INC (US) 2014-01-22 EP claimed
EP-2197879-A1 C7-SUBSTITUTED CAMPTOTHECIN ANALOGS BIONUMERIK PHARMACEUTICALS, INC. (US) 2010-06-23 EP claimed
US-7687496-B2 C7-substituted camptothecin analogs BIONUMERIK PHARMACEUTICALS, INC. (US) 2010-03-30 US claimed
WO-2009051580-A1 C7-SUBSTITUTED CAMPTOTHECIN ANALOGS BIONUMERIK PHARMACEUTICALS, INC. (US) 2009-04-23 WO claimed
US-20090099224-A1 C7- substituted camptothecin analogs BIONUMERIK PHARMACEUTICALS, INC. 2009-04-16 US claimed
CN-1169791-C Novel acetamide derivatives and protease inhibitors �ձ���ҩ��ʽ���� 2004-10-06 CN claimed
US-6271238-B1 USEFUL IN TREATING AND PREVENTING DISEASES INVOLVING CHYMOTRYPSIN TYPE PROTEASES WHICH ARE RELATED TO ASTHMA, ALLERGY, INFLAMMATIONS, RHEUMATISM, HYPERTENSION, HEART FAILURE, MYOCARDIAL INFARCTION, AND CARDIAC HYPERTROPHY NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2001-08-07 US claimed
EP-1055683-A1 NOVEL ACETAMIDE DERIVATIVE AND USE THEREOF Nippon Kayaku Kabushiki Kaisha (JP) 2000-11-29 EP claimed
CN-1229405-A Novel acetamide derivatives and protease inhibitors NIPPON KAYAKU KK (JP) 1999-09-22 CN claimed
EP-0936216-A1 NOVEL ACETAMIDE DERIVATIVES AND PROTEASE INHIBITORS NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1999-08-18 EP claimed
US-20070032466-A1 Drug containing chymase inhibitor as the active ingredient TEIJIN PHARMA LIMITED (JP) 2007-02-08 US disclosed
EP-1666067-A1 DRUG CONTAINING CHYMASE INHIBITOR AS THE ACTIVE INGREDIENT Teijin Pharma Limited (JP) 2006-06-07 EP disclosed
CN-1169791-C Novel acetamide derivatives and protease inhibitors �ձ���ҩ��ʽ���� 2004-10-06 CN disclosed
US-6300337-B1 Acetamide derivative and use thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2001-10-09 US disclosed
US-6271238-B1 USEFUL IN TREATING AND PREVENTING DISEASES INVOLVING CHYMOTRYPSIN TYPE PROTEASES WHICH ARE RELATED TO ASTHMA, ALLERGY, INFLAMMATIONS, RHEUMATISM, HYPERTENSION, HEART FAILURE, MYOCARDIAL INFARCTION, AND CARDIAC HYPERTROPHY NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2001-08-07 US disclosed
EP-1055683-A1 NOVEL ACETAMIDE DERIVATIVE AND USE THEREOF Nippon Kayaku Kabushiki Kaisha (JP) 2000-11-29 EP disclosed
CN-1229405-A Novel acetamide derivatives and protease inhibitors NIPPON KAYAKU KK (JP) 1999-09-22 CN disclosed
EP-0936216-A1 NOVEL ACETAMIDE DERIVATIVES AND PROTEASE INHIBITORS NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1999-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099224-A1 C7- substituted camptothecin analogs ABCB1, ABCC1, ABCG2 L3MBTL1 1295/4885POLB 1624/4885NPSR1 4518/4885
US-20070032466-A1 Drug containing chymase inhibitor as the active ingredient REN, SERPINB1, CMA1 L3MBTL1 4241/4885POLB 3771/4885NPSR1 1683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.